Three hundred thousand American deaths in three years…and the chemistry is still evolving. If the cartels turned the lab into the battlefield, why haven’t we brought our own defenses?

In this investigation, host Michael Brown sits down with Collin Gage, CEO and co-founder of ARMR Sciences, to unpack a controversial but potentially game-changing idea: an immunotherapy “vaccine” designed to block fentanyl from reaching the brain. Gage explains the planned Phase I/II human trial, why military and first responders could be the first beneficiaries, and how a platform could expand to multivalent shields against carfentanil and emerging analogs.

We press the hard questions: pharmaceutical-grade versus “cartel” fentanyl, risk-compensation behavior, and whether the U.S. should treat this as biodefense.

Expect an unflinching discussion about creating anti-narco-chemistry that removes the “high” and, with it, the business model. It’s exactly the kind of debate a country losing hundreds of people each day must have, if we want a fentanyl-free future.

Views expressed in this material are opinions of the host and the guest, and do not necessarily reflect the views of Rigaku Analytical Devices.